Published 2 days ago • loading... • Updated 2 days ago

Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment

Summary by WBOC 16

Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s

+3 Reposted by 3 other sources

Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s

2 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources4

Leaning Left2Leaning Right1Center1Last Updated2 days agoBias Distribution

50% Left

50% Left

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

The Record broke the news in Waterloo, Canada 2 days ago on Wednesday, June 10, 2026.

Sources are mostly out of (0)